Efficacy of GSK Biologicals' candidate tuberculosis (TB) vaccine GSK 692342 against TB disease, in healthy adults living in a TB endemic region

Trial Profile

Efficacy of GSK Biologicals' candidate tuberculosis (TB) vaccine GSK 692342 against TB disease, in healthy adults living in a TB endemic region

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 19 Feb 2018

At a glance

  • Drugs GSK 692342 (Primary)
  • Indications Tuberculosis
  • Focus Therapeutic Use
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 19 Feb 2018 According to an Aeras media release, data regarding Learnings associated with the impact of implementing an effective community engagement strategy on retention rates in this study will be presented at the Global Forum on TB Vaccines 2018.
    • 12 Jan 2018 Planned End Date changed from 22 Oct 2018 to 25 Nov 2018.
    • 12 Jan 2018 Planned primary completion date changed from 22 Oct 2018 to 25 Nov 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top